ADIPOQ and chronic kidney disease: Because a series of previous reports have shown the development of adiponectin resistance following receptor activation in chronic kidney disease (CKD) patients9, it is important to elucidate the mechanism(s) that might contribute to the reversal of the inverse association observed in the general population mentioned above to a positive one in haemodialysis patients.